	US 11,911,414 B2
	Regulatory T cell epitopes
Anne De Groot, Providence, RI (US); and William Martin, Providence, RI (US)
Assigned to EpiVax Inc., Providence, RI (US)
Filed by EpiVax Inc., Providence, RI (US)
Filed on Mar. 26, 2021, as Appl. No. 17/214,061.
Claims priority of provisional application 63/077,253, filed on Sep. 11, 2020.
Claims priority of provisional application 63/000,630, filed on Mar. 27, 2020.
Prior Publication US 2021/0308182 A1, Oct. 7, 2021
Int. Cl. A61K 35/17 (2015.01); A61K 35/12 (2015.01); C07K 7/08 (2006.01); C12N 5/0783 (2010.01)

CPC A61K 35/17 (2013.01) [C07K 7/08 (2013.01); C12N 5/0637 (2013.01); A61K 2035/122 (2013.01)]

9 Claims

1. A method of inducing regulatory T-cells to suppress immune response in a subject comprising administrating to the subject a therapeutically effective amount of a T-cell epitope composition, wherein the T-cell epitope composition comprises one or more isolated T-cell epitope polypeptides, wherein at least one isolated T-cell epitope polypeptide consists of the amino acid sequence of SEQ ID NO: 7.